82 related articles for article (PubMed ID: 30345693)
1. Blinded continuous monitoring in clinical trials with recurrent event endpoints.
Friede T; Häring DA; Schmidli H
Pharm Stat; 2019 Jan; 18(1):54-64. PubMed ID: 30345693
[TBL] [Abstract][Full Text] [Related]
2. The inclusion of real world evidence in clinical development planning.
Martina R; Jenkins D; Bujkiewicz S; Dequen P; Abrams K;
Trials; 2018 Aug; 19(1):468. PubMed ID: 30157904
[TBL] [Abstract][Full Text] [Related]
3. Analysis and design of randomised clinical trials involving competing risks endpoints.
Tai BC; Wee J; Machin D
Trials; 2011 May; 12():127. PubMed ID: 21595883
[TBL] [Abstract][Full Text] [Related]
4. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
Waleed M; He J; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
[TBL] [Abstract][Full Text] [Related]
5. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
Roig MB; Melis GG; Posch M; Koenig F
Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
[TBL] [Abstract][Full Text] [Related]
6. Statistical Considerations and Software for Designing Sequential, Multiple Assignment, Randomized Trials (SMART) with a Survival Final Endpoint.
Kravets S; Ruppert AS; Jacobson SB; Le-Rademacher JG; Mandrekar SJ
J Biopharm Stat; 2024 Jul; 34(4):539-552. PubMed ID: 37434437
[TBL] [Abstract][Full Text] [Related]
7. Bayesian analysis of multi-type recurrent events and dependent termination with nonparametric covariate functions.
Lin LA; Luo S; Chen BE; Davis BR
Stat Methods Med Res; 2017 Dec; 26(6):2869-2884. PubMed ID: 26546256
[TBL] [Abstract][Full Text] [Related]
8. Distributional imputation for the analysis of censored recurrent events.
Fairfax SR; Yang S
Stat Med; 2024 Jun; 43(13):2622-2640. PubMed ID: 38684331
[TBL] [Abstract][Full Text] [Related]
9. Sample size considerations for split-mouth design.
Zhu H; Zhang S; Ahn C
Stat Methods Med Res; 2017 Dec; 26(6):2543-2551. PubMed ID: 26303156
[TBL] [Abstract][Full Text] [Related]
10. Optimal allocation strategies in platform trials with continuous endpoints.
Bofill Roig M; Glimm E; Mielke T; Posch M
Stat Methods Med Res; 2024 May; 33(5):858-874. PubMed ID: 38505941
[TBL] [Abstract][Full Text] [Related]
11. Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes.
Homma G; Yoshida T
Pharm Stat; 2024; 23(1):46-59. PubMed ID: 38267827
[TBL] [Abstract][Full Text] [Related]
12. An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology.
Dodd LE; Korn EL; Freidlin B; Gu W; Abrams JS; Bushnell WD; Canetta R; Doroshow JH; Gray RJ; Sridhara R
Clin Trials; 2013 Oct; 10(5):754-60. PubMed ID: 23935162
[TBL] [Abstract][Full Text] [Related]
13. Design and monitoring of clinical trials with an interim analysis and a negative binomial endpoint.
Quan H; Xu Y; Liu Y; Chen X
Contemp Clin Trials; 2024 Mar; 138():107467. PubMed ID: 38331382
[TBL] [Abstract][Full Text] [Related]
14. Identification of causal effects on binary outcomes using structural mean models.
Clarke PS; Windmeijer F
Biostatistics; 2010 Oct; 11(4):756-70. PubMed ID: 20522728
[TBL] [Abstract][Full Text] [Related]
15. An audit strategy for progression-free survival.
Dodd LE; Korn EL; Freidlin B; Gray R; Bhattacharya S
Biometrics; 2011 Sep; 67(3):1092-9. PubMed ID: 21210772
[TBL] [Abstract][Full Text] [Related]
16. Sample size determination.
Dell RB; Holleran S; Ramakrishnan R
ILAR J; 2002; 43(4):207-13. PubMed ID: 12391396
[TBL] [Abstract][Full Text] [Related]
17. Clinical Trial Adaptation by Matching Evidence in Complementary Patient Sub-groups of Auxiliary Blinding Questionnaire Responses.
Arandjelović O
PLoS One; 2015; 10(7):e0131524. PubMed ID: 26161797
[TBL] [Abstract][Full Text] [Related]
18. Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.
Ando Y; Hamasaki T; Evans SR; Asakura K; Sugimoto T; Sozu T; Ohno Y
Stat Biopharm Res; 2015 Jun; 7(2):81-94. PubMed ID: 26167243
[TBL] [Abstract][Full Text] [Related]
19. Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks.
Furberg JF; Andersen PK; Scheike T; Ravn H
Pharm Stat; 2024 Mar; ():. PubMed ID: 38509020
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal design considerations to optimize power to detect variances and covariances among rates of change: simulation results based on actual longitudinal studies.
Rast P; Hofer SM
Psychol Methods; 2014 Mar; 19(1):133-54. PubMed ID: 24219544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
